The B cell: A new therapeutic target in rheumatoid arthritis and other autoimmune diseases

Joint Bone Spine

Volumn 71, Issue 5, 2004, Pages 357-360

  Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Anti CCP antibodies; Anti GPI antibodies; Autoimmune disease; B lymphocyte; BAFF; BlyS; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIBODY; AUTOANTIBODY; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; MONOCLONAL ANTIBODY; RITUXIMAB; TUMOR NECROSIS FACTOR;

ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL TRIAL; CYTOLYSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EDITORIAL; HUMAN; INJECTION; NONHUMAN; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; HUMANS; MEMBRANE PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5044225295     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2003.12.005     Document Type: Editorial

References (23)

1. Kouskoff V., Korganow A.S., Duchatelle V., Degott C., Benoist C., Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:1996;811-822
2. Matsumoto I., Staub A., Benoist C., Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 286:1999;1732-1735
3. Matsumoto I., Maccioni M., Lee D.M., Maurice M., Simmons B., Brenner M., et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat Immunol. 4:2002;360-365
4. Matsumoto I., Lee D.M., Goldbach-Mansky R., Sumida T., Hitchon C.A., Schur P.H., et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 48:2003;944-954
5. Zeng X., Ai M., Tian X., Gan X., Shi Y., Song Q., et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol. 30:2003;1451-1455
6. Baeten D., Peene I., Union A., Meheus L., Sebbag M., Serre G., et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium. Arthritis Rheum. 44:2001;2255-2262
7. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 34:2003;395-402
8. Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 189:1999;1639-1648
9. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 404:2000;995-999
10. Groom J., Kalled S.L., Cutler A.H., Olson C., Woodcock S.A., Schneider P., et al. Association of BAFF/BlyS overexpression with Sjögren's syndrome. J Clin Invest. 109:2002;59-68
11. Mariette X., Roux S., Zhang J., Bengoufa D., Lavie F., Zhou T., et al. The level of BLYS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 62:2003;168-171
12. Edwards J.C.W., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology. 40:2001;205-211
13. Leandro M.J., Edwards J.C.W., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 61:2002;883-888
14. Stahl H.D., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Edwards J.C.W., Close D.R., et al. Rituximab in RA: efficacy and safety from a randomised, controlled trial. Ann Rheum Dis. 62:(Suppl 1):2003;OP0004
15. Cambridge G., Leandro M.J., Edwards J.C.W., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48:2003;2146-2154
16. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46:2002;2673-2677
17. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcγRIIIa genotype to the degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:2003;455-459
18. Somer B.G., Tsai D.E., Downs L., Weinstein B., Schuster S.J. Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Care Res. 49:2003;394-398
19. Sansonno D., De Re V., Lauletta G., Tucci F.A., Boiocchi M., Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 101:2003;3818-3826
20. Zaja F., De Vita S., Mazzaro C., Sacco S., Damiani D., De Marchi G., et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 101:2003;3827-3834
21. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 98:2001;952-957
22. Quartier P., Brethon B., Philippet P., Landman-Parker J., Le Deist F., Fischer A. Treatment of childhood auto-immune haemolytic anaemia with rituximab. Lancet. 358:2001;1511-1513
23. Remuzzi G., Chiurchiu C., Abbate M., Brusegan V., Bontempelli M., Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet. 360:2002;923-924